Next Phase Newsletter

Headquartered in London and New York with offices worldwide, a private equity firm managing ~$65M in assets under management (AUM). The firm invests in both public and private markets across various industries, with a healthcare-focused team dedicated to private market investments. Their average initial check size ranges from $10M to $30M, with follow-on investments expected. The firm has the ability to led, co-lead, or join a round as a syndicate member.

The firm is interested in opportunities in therapeutics, medical devices, and diagnostics. The firm is agnostic to subsectors and indications and is willing to consider orphan drugs. Within therapeutics, they prefer asset-forward companies but are open to platform companies with lead assets or drugs. Regarding the phase of development, the firm seeks clinical stage companies or companies that are no more than 6-9 months away from the clinical stage.

The firm doesn’t have specific requirements for companies’ management teams. The firm will consider board or observer seats on a case-by-case basis, but this is not a requirement.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A boutique venture capital firm headquartered in Boston with a global outreach and epicenter in Dubai has invested alongside Tier 1 VCs in 12 companies with 5 exits qualified as unicorns. The firm is stage-agnostic and can invest at any stage. With this said, check sizes are flexible and can range from $500K – $15M. Their capital comes mostly from qualified purchasers (investors) located in the MENA region at large and GCC region specifically. To date, the firm has invested in USA based companies.

The firm is focused on healthcare, energy, ICT and infotech and most recently data defined networks addressing the systems aging and longevity (and research at large) pain points. The firm has invested in medi-tech, health-tech and biotech in the past which includes but not limited to diagnostics, medical devices, therapeutics, and digital health. The firm invests within 4 pillars of longevity roadmap covering health span and lifespan namely: (a) preventative, (b) replacement, (c) biostasis, and (d) therapeutics and genetic engineering on the basis that they are targeting systems aging and longevity. The firm prefers a management team with domain expertise, past performance and PhD’s / higher educational pedigree.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital and private equity firm making investments in life sciences will invest as early as Series A and through growth transactions. The firm looks to invest between $10 million and $40 million per investment. The firm has a preference for funding companies with a de-risked clinical development pathway, often via established mechanisms of action, repurposed/reformulated programs, 505(b)(2)s, and/or proof of concept clinical efficacy data. 
 
The firm has a primary focus on pharmaceuticals / therapeutics, and a secondary focus on medical devices. The firm is agnostic to indication. 
 
The firm plays an active role in their portfolio companies. The firm will take a board seat with any company in which they invest.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm with ties to a family office invests mainly in Seed to Series A/B, with an initial check ranging between 3-7 million Euros. Follow-on investments are possible, and the firm may invest up to 15 million Euros throughout the life cycle. The firm is open to both leading and co-investing. The firm focuses on opportunities in Europe, UK and US. 
 
The firm is interested in early-stage therapeutic technologies. The firm is agnostic regarding modalities and indications, and is open to exploring different types of therapeutic assets. Additionally, the firm has invested in orphan drugs. While there is no strict mandate for the development phases of assets, having at least in-vivo data would generally be preferred. 
 
There are no specific requirements for companies’ management team.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A venture capital firm founded in 2019 and headquartered in Europe invests in healthtech startups in Pre-Seed to Seed stages across Europe as well as in the U.S., Canada, Israel, and Australia. Typical check size ranges from €200k-1.5M EUR, and the firm can lead rounds, co-invest, or follow. 
 
The firm invests in healthcare companies that involves data information, technology, hardware, software, AI, and medtech that includes a strong data or computing component. The firm will not look at traditional medical devices such as surgical devices that does not have data components or traditional biotech such as therapeutics and drug development. The firm has broad indications and will look at different needs across the entire healthcare system such as need-based solutions for providers, better operations on the backend, direct solutions for patients, clinical trial needs, payer and insurance company solutions, and medical education platforms. 
 
The firm often takes a board or observer seat though not required. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A USA-based venture capital firm that focuses on partnering with digital health startups that will redefine the healthcare system. The firm partners with incubation, Seed, Series A, and Series B startups to drive innovation within the healthcare system to create fundamental change with typical check sizes of $1-15m. The firm is excited about all opportunities in digital health and invests across all business models (B2B, B2B2B, and DTC) and customer segments (payer, provider, employer, pharma, government, customer, etc.). The firm is willing to invest globally and focuses on companies who are looking to commercialize in the US. 
 
The firm is interested in all sectors of digital health, which generally includes five distinct areas: consumer gateways, data liquidity and analytics, tech-enabled services, digital therapeutics, and vertical reimagination.  
 
The firm prefers to lead or co-lead its investments across all stages. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.

A leading Europe-based venture capital firm provides private equity financing to early- and mid-stage, highly innovative life science companies bringing life-changing therapeutic treatments to patients, with a focus on indications with high unmet needs. The firm has a diverse international team that is driven by science, with the ambition to transform capital into medical breakthroughs. The firm was founded in 2008 and has over 400M€ million in assets under management through its three funds. The investments typically range from 5 million to 20 million, including additional capital for follow-on investments. 
 
The firm invests in innovative therapeutics. The firm focuses on indications with a clear unmet need, and prefers to invest in opportunities that have realistic exit potential in 2-3 years. In case of niche/orphan indications, the potential market share should be significant and realistic. The firm invests in small molecules, biologics and advanced therapies. At minimum, the product should have solid animal data. 
 
The firm looks for a cohesive management team with a proven track record, including relevant business experience and top-notch scientific know-how. The firm requires a board seat in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.